ARA
NYSEAmerican Renal Associates Holdings, Inc
American Renal Associates Holdings, Inc (ARA) is a Misc Health and Biotechnology Services company listed on NYSE. There were no new wire items for ARA in the last 30 days. The most recent was published Feb 5, 2021.
Latest news
25 items- SECSEC Form 15-12B filed15-12B - American Renal Associates Holdings, Inc. (0001498068) (Filer)
- SECSEC Form EFFECT filedEFFECT - American Renal Associates Holdings, Inc. (0001498068) (Filer)
- SECSEC Form SC 13G/A filedSC 13G/A - American Renal Associates Holdings, Inc. (0001498068) (Subject)
- INSIDERSEC Form 4 filed by P L Partners Capital Centerbridge4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
- INSIDERSEC Form 4: W Thomas Erickson disposed to the issuer $0 worth of Common Stock (67,755 units at $0.00), decreasing ownership by 100% to 0 units4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
- INSIDERSEC Form 4: J Christopher Hocevar disposed to the issuer $0 worth of Common Stock (18,679 units at $0.00), decreasing ownership by 100% to 0 units4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
- INSIDERSEC Form 4: A Joseph Carlucci disposed to the issuer $0 worth of Common Stock (1,245,164 units at $0.00), decreasing ownership by 100% to 0 units4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
- INSIDERSEC Form 4: M John Jureller disposed to the issuer $0 worth of Common Stock (49,435 units at $0.00), decreasing ownership by 100% to 0 units4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
- INSIDERSEC Form 4: T Syed Kamal disposed to the issuer $0 worth of Common Stock (1,291,236 units at $0.00), decreasing ownership by 100% to 0 units4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
- INSIDERSEC Form 4: Victoria Labriola disposed to the issuer $0 worth of Common Stock (64,569 units at $0.00), decreasing ownership by 100% to 0 units4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
- INSIDERSEC Form 4: H Robert Fish disposed to the issuer $0 worth of Common Stock (43,205 units at $0.00), decreasing ownership by 100% to 0 units4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
- INSIDERSEC Form 4: E Don Williamson disposed to the issuer $0 worth of Common Stock (307,282 units at $0.00), decreasing ownership by 100% to 0 units4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
- INSIDERSEC Form 4: Michael Boxer disposed to the issuer $0 worth of Common Stock (100,468 units at $0.00), decreasing ownership by 100% to 0 units4 - American Renal Associates Holdings, Inc. (0001498068) (Issuer)
- SECSEC Form POS AM filedPOS AM - American Renal Associates Holdings, Inc. (0001498068) (Filer)
- SECSEC Form S-8 POS filedS-8 POS - American Renal Associates Holdings, Inc. (0001498068) (Filer)
- SECSEC Form 25-NSE filed25-NSE - American Renal Associates Holdings, Inc. (0001498068) (Subject)
- SECSEC Form 8-K filed8-K - American Renal Associates Holdings, Inc. (0001498068) (Filer)
- PRAmerican Renal Associates Completes Transaction With Innovative Renal Care, a Nautic Partners Portfolio CompanyBEVERLY, Mass.--(BUSINESS WIRE)--Nautic Partners and its portfolio company, Innovative Renal Care (IRC), have completed the previously announced transaction to acquire American Renal Associates Holdings, Inc. (NYSE: ARA), effective January 25, 2021. The transaction creates a unique opportunity to shape the future of kidney care during a dynamic time of change, innovation and transformation in the industry. “As the healthcare industry continues to evolve, recent innovation throughout kidney and renal care has allowed for dramatic and exciting improvements in care delivery and patient experience,” said Nick Mendez, president and CEO of IRC. “ARA’s significant infrastructure and geo
- SECSEC Form 8-K filed8-K - American Renal Associates Holdings, Inc. (0001498068) (Filer)
- SECSEC Form DEFA14A filedDEFA14A - American Renal Associates Holdings, Inc. (0001498068) (Filer)
- PRSHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers; Investors are Encouraged to Contact the Firm – EIDX, WTRE, ARA, CITNEW YORK, Nov. 07, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Eidos Therapeutics, Inc. (NASDAQ: EIDX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to BridgeBio Pharma, Inc. Under the merger agreement, Eidos stockholders will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash for each share of Eidos common stock owned. If you are an Eidos shareholder, click on this link to learn more about your rights and options: https://halpersadeh.com/actions/eidos-therapeutics-inc-eidx-stock-merger-bridgebio/. Watford Holdings Ltd. (NASDAQ: WT
- PRLifshitz Law Firm, P.C. Announces Investigation of American Renal Associates Holdings, Inc., BMC Stock Holdings, Inc., Callaway Golf Company, Cellular Biomedicine Group, Inc., CIT Group Inc., Eidos Therapeutics, Inc., Watford Holdings Ltd. and Yintech Investment Holdings LimitedNEW YORK, Nov. 6, 2020 /PRNewswire/ -- American Renal Associates Holdings, Inc. (NYSE: ARA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ARA to affiliates of Nautic Partners for $11.50 per share. If you are a ARA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. BMC Stock Holdings, Inc. (NASDAQ: BMCH) - Builders FirstSource, Inc. (NASDAQ: BLDR) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the
- PRAmerican Renal Associates Holdings, Inc. Announces Third Quarter 2020 ResultsBEVERLY, Mass.--(BUSINESS WIRE)--American Renal Associates Holdings, Inc. (NYSE: ARA) (the “Company”), a leading kidney care and dialysis provider focused on partnering with local nephrologists, today announced financial and operating results for the third quarter ended September 30, 2020. Certain metrics, including those expressed on an adjusted basis, are Non-GAAP financial measures (See “Use of Non-GAAP Financial Measures” and the reconciliation tables further below). Third Quarter 2020 Highlights (all percentage changes compare Q3 2020 to Q3 2019 unless noted): Patient service operating revenues decreased 0.8% to $209.7 million; Net income attributable to American Renal As
- PRALERT: Halper Sadeh LLP Reminds Shareholders About Its Ongoing Merger Investigations; Investors are Encouraged to Contact the Firm - EIDX, RESI, PE, ARANEW YORK, Oct. 31, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Eidos Therapeutics, Inc. (NASDAQ: EIDX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to BridgeBio Pharma, Inc. Under the merger agreement, Eidos stockholders will receive either 1.85 shares of BridgeBio common stock or $73.26 in cash for each share of Eidos common stock owned. If you are an Eidos shareholder, click on this link to learn more about your rights and options: https://halpersadeh.com/actions/eidos-therapeutics-inc-eidx-stock-merger-bridgebio/. Front Yard Residential Corporation
- PRLifshitz Law Firm, P.C. Announces Investigation of American Renal Associates Holdings, Inc. (NYSE: ARA), Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), and CIT Group Inc. (NYSE:CIT) and Mid-Con Energy Partners, LP (NASDAQ: MCEP)NEW YORK, Oct. 30, 2020 (GLOBE NEWSWIRE) -- American Renal Associates Holdings, Inc. (NYSE: ARA) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of ARA to affiliates of Nautic Partners for $11.50 per share. If you are a ARA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@jlclasslaw.com. Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of CBMG to members
ARA FAQ
6 questionsWhat is the latest news on ARA?
Quantisnow has not tracked any new filings, ratings or press releases for ARA in the last 30 days. The most recent wire item was published on February 5, 2021.Where does ARA stock trade?
American Renal Associates Holdings, Inc (ARA) is listed on NYSE.What sector and industry is ARA in?
American Renal Associates Holdings, Inc operates in the Health Care sector, Misc Health and Biotechnology Services industry.When did American Renal Associates Holdings, Inc go public?
American Renal Associates Holdings, Inc (ARA) completed its IPO in 2016.What companies are similar to ARA?
Notable peers in the same industry include PARK (Park Dental Partners Inc.), FMS (Fresenius Medical Care AG), PGNY (Progyny Inc.), VMD (Viemed Healthcare Inc.), AGL (agilon health inc.). Compare ARA side-by-side with any of them on Quantisnow.How can I track ARA on Quantisnow?
Quantisnow aggregates American Renal Associates Holdings, Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARA to receive live email and push alerts on every new disclosure.